BEVACIZUMAB AS 4TH LINE TREATMENT IN METASTATIC COLORECTAL CANCER

被引：0
|
作者：
Cannella, Lucia [1 ]
Carlomagno, Chiara [1 ]
De Stefano, Alfonso [1 ]
Alfieri, Salvatore [1 ]
Colantuoni, Maria [1 ]
Cella, Chiara [1 ]
De Placido, Sabino [1 ]
机构：
[1] Univ Federico II, Dept Endocrinol & Mol & Clin Oncol, Naples, Italy
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：17 / 18
页数：2
相关论文
共 50 条
  • [21] Comment on 'Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer'
    Molina-Garrido, M. J.
    Guillen-Ponce, C.
    BRITISH JOURNAL OF CANCER, 2011, 104 (01) : 224 - 225
  • [22] Bevacizumab with chemotherapy for the first-line treatment of metastatic colorectal cancer: "NCI Slovakia" results
    Dolinsky, J.
    Salek, T.
    Hlavata, Z.
    Ivancova, H.
    Risnyovszka, Z.
    Mardiak, J.
    Koza, I
    ANNALS OF ONCOLOGY, 2006, 17 : 70 - 70
  • [23] Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer:The OBELIX study
    Lorenzo Antonuzzo
    Elisa Giommoni
    Davide Pastorelli
    Tiziana Latiano
    Ida Pavese
    Domenico Azzarello
    Michele Aieta
    Ilaria Pastina
    Francesca Di Fabio
    Alessandro Bertolini
    Domenico Cristiano Corsi
    Selene Mogavero
    Valentina Angelini
    Mario Pazzagli
    Francesco Di Costanzo
    World Journal of Gastroenterology, 2015, (23) : 7281 - 7288
  • [24] Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings
    Giantonio, Bruce J.
    SEMINARS IN ONCOLOGY, 2006, 33 (05) : S15 - S18
  • [25] Comment on ‘Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer’
    M J Molina-Garrido
    C Guillén-Ponce
    British Journal of Cancer, 2011, 104 : 224 - 225
  • [26] Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    Feliu, J.
    Barriuso, J.
    BRITISH JOURNAL OF CANCER, 2011, 104 (01) : 226 - 226
  • [27] Combination of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: Slovakian experience
    Salek, T.
    Mego, M.
    Mardiak, J.
    Andrasina, I.
    Spanik, S.
    Malec, V.
    Barilla, R.
    Riedelova, K.
    Benedikty, A.
    Dammak, A.
    Porsok, S.
    Svabova, V.
    Chovanec, M.
    Cipkova, A.
    Usakova, V.
    Siskova, M.
    Jurisova, S.
    Dolinsky, J.
    Hlavata, Z.
    Andrezalova, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [28] Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer
    Akun, E.
    Okutur, K.
    Seber, S.
    Korkmaz, T.
    Aydin, K.
    Bozkurt, M.
    Namal, E.
    Hasbal, B.
    Tecimer, C.
    Demir, G.
    JOURNAL OF BUON, 2012, 17 (04): : 669 - 676
  • [29] Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer
    Tsutsumi, Soichi
    Fujii, Takaaki
    Yamaguchi, Satoru
    Suto, Toshinaga
    Yajima, Reina
    Morita, Hiroki
    Kato, Toshihide
    Asao, Takayuki
    Kuwano, Hiroyuki
    HEPATO-GASTROENTEROLOGY, 2014, 61 (131) : 633 - 637
  • [30] PHARMACOECONOMICS ANALYSIS OF TREATMENT OF METASTATIC COLORECTAL CANCER WITH BEVACIZUMAB IN BRAZIL
    Tonon, L. M.
    Secoli, S. R.
    VALUE IN HEALTH, 2009, 12 (07) : A497 - A497
12345